All Reports Events Blogs Videos
Showing 227 results
  • NEW
    Blog
    Aug. 03, 2026

    In Part 1 of this series, Why the Migration Clock Has Already Started, we explained why Banking, Financial Services and Insurance (BFSI) enterprises cannot wait for a formal mandate to begin their Post-quantum Cryptography (PQC) migration and estimated a roughly US$7 billion spending opportunity across the top…
  • Tech Launch Perspective
    July 22, 2026

    Life sciences enterprises are moving beyond isolated generative AI pilots toward governed, multi-agent workflows that support clinical, commercial, and real-world activities. This shift is increasing demand for platforms that combine regulatory-grade data governance, enterprise interoperability, scalable…
  • Blog
    July 21, 2026

    Current state of cryptography in BFSI  Banks, insurers, and capital markets enterprises have been using cryptography for a long time across every important part of their business. It protects everything from mobile payments to complex trading platforms and third-party connections.  …
  • Video
    June 12, 2026

    Clinical development teams must manage trial complexity, fragmented data, slower patient recruitment, and tighter regulatory scrutiny, with AI options offering an appealing solution to these operational challenges. Everest Group’s report, Innovation Watch: AI Applications in Clinical…
  • May 26, 2026

    Clinical development teams must manage trial complexity, fragmented data, slower patient recruitment, and tighter regulatory scrutiny, with AI options offering an appealing solution to these operational challenges. Everest Group’s report, Innovation Watch: AI Applications in Clinical…
  • Roundtable
    April 16, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Thursday, May 07, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Roundtable
    March 31, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Tuesday, April 14, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • See Us At
    March 16, 2026

      Join Nisarg Shah, Practice Director at Everest Group, for a webinar on Beyond Pilots: Scaling Trusted AI in Clinical Trial Documentation. AI adoption in clinical trials is accelerating, yet many organizations still struggle to move…
  • Tech Launch Perspective
    Feb. 26, 2026

    Life sciences enterprises are under pressure to accelerate research, improve evidence generation, and operationalize AI across clinical and commercial functions. Fragmented data estates, evolving regulatory requirements, and the growing importance of real-world and genomic data are…
  • State of the Market
    Feb. 25, 2026

    The clinical development technology market transform as life sciences enterprises increasingly rely on digital and AI-enabled solutions to manage rising costs, complex regulatory demands, and longer development cycles. This State of the Market report outlines how…
  • Video
    Feb. 10, 2026

    Everest Group’s PEAK Matrix® Assessment assesses RTSM providers through the lens of buyer impact and delivery capability. In this deep dive, Nisarg Shah, Practice Director, and Kayva Murki, Senior Analyst, analyze the RTSM provider market in…
  • Video
    Feb. 10, 2026

    The PEAK Matrix® Assessment provides a structured evaluation of RTSM providers’ strengths, scale, and differentiation in the market. Nisarg Shah, Practice Director, and Kayva Murki, Senior Analyst, explore the major growth drivers accelerating RTSM adoption. They…
  • Video
    Feb. 10, 2026

    Everest Group’s PEAK Matrix® Assessment evaluates RTSM providers based on market impact and vision & capability. In this video, Nisarg Shah, Practice Director, and Kayva Murki, Senior Analyst, unpack findings from the inaugural RTSM PEAK Matrix®…
  • Innovation Watch
    Jan. 08, 2026

    AI has emerged as a transformative force in clinical development, by enhancing decision-making, automating manual processes, and improving trial execution across the value chain. This report explores generative, agentic, and advanced AI’s growing influence in the…
  • Provider Compendium
    Dec. 17, 2025

    Life sciences organizations are increasingly prioritizing automation, configurability, and real-time visibility to support modern clinical trial requirements. As adaptive designs, decentralized models, and global multi-protocol studies become more prevalent, the role of Randomization and Trial Supply…
  • Provider Compendium
    Nov. 25, 2025

    Life sciences enterprises are accelerating their shift to modern digital platforms to meet evolving demands for agility, patient-centricity, and regulatory compliance. Traditional ERP and CRM systems are giving way to cloud-based platforms that enable intelligent, connected…
  • PEAK Matrix®
    Nov. 25, 2025

    With global and adaptive clinical trials’ rising complexities, life sciences organizations are increasingly adopting intelligent Randomization and Trial Supply Management (RTSM) platforms to enhance operational efficiency, ensure regulatory compliance, and safeguard patient integrity. RTSM systems have…
  • Blog
    Nov. 05, 2025

    In 2006, I visited my first captive center in Bengaluru. At the time, the model was still in its formative years – many multinational organizations were only beginning to explore the potential of setting up their own in-house centers…
  • Blog
    Nov. 04, 2025

    In an era of increasingly complex clinical trials, Risk-Based Quality Management (RBQM) has emerged as more than a regulatory mandate, it is a strategic imperative. Traditional monitoring methods, reliant on exhaustive on-site visits and 100% Source…
  • Tech Provider Spotlight
    Oct. 14, 2025

    Clinical trial complexity continues to increase with hybrid study models, diverse data sources, and growing regulatory expectations, making traditional oversight models inadequate. Conventional monitoring approaches reliant on 100% source data verification and frequent on-site visits are…

Items per page